Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate : a prospective international cohort study by Mocroft, Amanda et al.
Population Pharmacokinetic and Pharmacodynamic Analysis
To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir
Disoproxil Fumarate in People Living with HIV-1
Pavan Vaddady,a Bhargava Kandala,a Ka Lai Yeea
aMerck & Co., Inc., Kenilworth, New Jersey, USA
ABSTRACT Doravirine is a non-nucleoside reverse transcriptase inhibitor for treat-
ment of human immunodeficiency virus type 1 (HIV-1) infection. A population phar-
macokinetic (PK) model for treatment-naive participants in doravirine clinical studies
was updated with data from switch participants in the DRIVE-SHIFT trial and used
to estimate individual post hoc PK parameter values and evaluate the efficacy
exposure-response relationship. The results support the 100-mg dose for people
living with HIV switching to a doravirine-based regimen (This study has been reg-
istered at ClinicalTrials.gov under ClinicalTrials registration no. NCT02397096.)
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People living with HIV require lifelong antiretroviral (ARV) treatment and may switchbetween several ARV regimens due to poor adherence or adverse events (1, 2).
Doravirine (DOR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) available as
single entity (3) and as a fixed-dose combination with nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs) lamivudine (3TC) and tenofovir disoproxil fumarate
(TDF). DOR/3TC/TDF is approved for the treatment of HIV-1 infection in adults who have
not received prior ARV treatment or who are virologically suppressed on a stable ARV
regimen that can be appropriately replaced by DOR/3TC/TDF (4). DOR is generally well
tolerated in humans, with no relevant drug-related adverse events (5–8).
DRIVE-SHIFT (7) (protocol MK-1439A-024; ClinicalTrials registration no. NCT02397096), a
phase 3, open-label, randomized, active-controlled, noninferiority trial in virologically
suppressed participants with HIV-1, evaluated a switch from a stable regimen of two
NRTIs plus a ritonavir- or cobicistat-boosted protease inhibitor, cobicistat-boosted
elvitegravir, or NNRTI to DOR/3TC/TDF. Participants were randomized (2:1) to switch to
DOR/3TC/TDF on day 1 (immediate switch group [ISG]) or to continue their baseline
regimen until week 24 and then switch to DOR/3TC/TDF (delayed switch group [DSG]).
The primary endpoint in DRIVE-SHIFT was the proportion of participants with an
HIV-1 RNA level of 50 copies/ml (U.S. Food and Drug Administration [FDA] snapshot
approach), with the primary comparison between ISG at week 48 and DSG at week 24.
The main objectives of the current analysis were to evaluate the consistency of DOR
pharmacokinetics (PK) in the ISG population with that of the treatment-naive popula-
tion described previously (9) and to evaluate the exposure-response relationship
between different quantiles of DOR exposure and the primary endpoint in ISG partic-
ipants to further inform on the efficacy and appropriateness of a switch to a DOR-based
regimen.
A total of 670 participants on stable ARV regimens were recruited to the DRIVE-
SHIFT trial (ISG, N  447; DSG, N  223) (7). DOR PK samples were collected from all
participants on day 1 (predose) and week 48 (predose and within 0.5 to 2 h postdose).
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Additional ISG PK samples were collected at weeks 4 (predose), 12 (irrespective of
dosing), and 24 (predose and 0.5 to 2 h postdose). Only PK data from the ISG were
included in the population PK analysis, given sparse sampling in the DSG (week 48
only).
To evaluate consistency of DOR PK in the phase 3 switch population with that of the
phase 3 treatment-naive population, several approaches (described in Text S1 in the
supplemental material) were evaluated. The exploratory analyses (approach 1) and
the estimation of the combined model (approach 3b) are presented here. Observed
data from DRIVE-SHIFT were initially compared with observed data from treatment-
naive participants within phase 3 trials (MK-1439-018 [P018], DRIVE-FORWARD, Clini-
calTrials registration no. NCT02275780; MK-1439A-021 [P021], DRIVE-AHEAD, Clinical-
Trials registration no. NCT02403674). A previously described population PK model for
the treatment-naive population (9) was updated in the current analysis using DOR
concentration data from the ISG of DRIVE-SHIFT. Population PK parameters, including
covariates, were reestimated, and the final model was used to estimate individual post
hoc PK parameter values for the switch and treatment-naive populations.
The population PK analysis data set comprised the original 341 healthy participants
and 959 treatment-naive participants with HIV-1, with the addition of 443 virologically
suppressed participants with HIV-1 from the DRIVE-SHIFT ISG (a total of 1,402 partici-
pants with HIV-1) (9). Four of 447 ISG individuals were excluded due to data reconcil-
iation issues. Comparison of PK data from treatment-naive participants in prior phase
3 studies with those from DRIVE-SHIFT suggested a comparable range of DOR concen-
trations at different steady-state time points (see Fig. S1 in the supplemental material)
and indicated the suitability of the previously developed population PK model for the
DRIVE-SHIFT ISG population PK analysis (7).
The original DOR population PK model was a one-compartment model with first-
order absorption and linear apparent clearance (CL/F). Body weight and healthy versus
HIV-1 infection status were covariates on apparent volume of distribution and age on
apparent clearance. This model characterized the ISG data well, as supported by the
diagnostic plots (see Text S1, Fig. S2, and Table S1 in the supplemental material).
The final PK parameters of the model (Table S1) were well estimated, with small
standard errors. These estimates were very similar to those of the previously developed
population PK model based only on data from healthy subjects and treatment-naive
participants with HIV-1 (9).
PK parameters, including area under the concentration-time curve from 0 to 24 h
(AUC0 –24), maximum serum concentration (Cmax), and plasma drug concentration 24 h
after dose administration (C24) at steady state, were simulated from post hoc compart-
mental parameter estimates for each participant in the phase 3 studies. Table 1 and Fig.
1 show the distributions of individual steady-state AUC0 –24, Cmax, and C24 from the
DRIVE-SHIFT ISG are comparable to those in treatment-naive phase 3 studies (P018 and
P021).
The AUC0 –24, Cmax, and C24 estimates for the DRIVE-SHIFT ISG were used in efficacy
TABLE 1 Summary statistics of DOR steady-state AUC0 –24, Cmax, and C24 following
administration of once-daily 100 mg DOR in treatment-naive study participants and
participants randomized to the ISG in the DRIVE-SHIFT trial (P024)a







Treatment naive (P018 and P021) 100 AUC0–24 (M · h) 730 38.1 28.8
C24 (nM) 730 932 62.7
Cmax (nM) 730 2,290 18.2
DRIVE-SHIFT ISG (P024) 100 AUC0–24 (M · h) 443 41.5 22.8
C24 (nM) 443 1,110 36.1
Cmax (nM) 443 2,390 16.5
aAUC0 –24, area under the concentration-time curve from 0 to 24 h; C24, plasma concentration 24 h after dose
administration; Cmax, maximum serum drug concentration; CV, coefficient of variation; DOR, doravirine; ISG,
immediate switch group; N, number of participants.
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exposure-response exploratory analyses for this population. The efficacy endpoints
used were the proportion of ISG participants maintaining HIV-1 RNA levels of 50
copies/ml and 40 copies/ml at week 48 (yes/no). Analyses were conducted for (i) the
primary snapshot approach specified in the phase 3 trial protocols that classified any
participant with missing data as a failure and (ii) the observed failure approach, where
monotone (nonintermittent) missing data for participants who discontinued treatment
prematurely due to lack of efficacy were assigned as failures after discontinuation,
whereas those with missing data for other reasons were excluded.
The exposure-response analysis data set included virological response data from
443 individuals. A linear exposure-effect model performed very similarly to the log
exposure-effect model based on the Akaike Information Criterion values; hence the
linear model was chosen for the analyses. The slope and 95% confidence interval (CI)
of the exposure-response relationship were estimated. A P value was calculated for the
slope to evaluate whether it was significant (nonzero) or insignificant (not different
from zero).
Slope estimates from the exposure-response analyses were not significantly differ-
ent from zero (P values of 0.05), suggesting a flat exposure-response relationship with
no trends between virologic response and DOR exposure over the range of exposures
achieved with once-daily 100-mg doses in the DRIVE-SHIFT ISG. Consequently, struc-
tural models of increased complexity were not explored and no covariate analysis was
performed. Figure 2 shows the exposure-response relationships with DOR steady-state
C24 (snapshot approach).
As DOR steady-state PK and exposure-response relationship are the same between







































FIG 1 Comparison of steady-state DOR (A) C24, (B) AUC0 –24, and (C) Cmax following administration of 100 mg once-daily DOR
between treatment-naive trials (P018 and P021) and participants from the ISG of DRIVE-SHIFT (P024). Boxes represent 25th, 50th,
and 75th percentiles. Whiskers represent the 5th and 95th percentiles of the respective distributions for C24, AUC0 –24, or Cmax.
AUC0 –24, area under the concentration-time curve from 0 to 24 h; C24, plasma concentration 24 h after dose administration; Cmax,
maximum serum drug concentration; DOR, doravirine; ISG, immediate switch group.
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acterized in the treatment-naive population, including the effects of intrinsic factors
and drug-drug interactions, is also applicable to the switch population. In patients
switching from efavirenz, a moderate cytochrome P450 (CYP) 3A inducer, plasma
concentrations of DOR may be transiently decreased as the induction effects of
efavirenz are washed out (10, 11). However, the efficacy and PK profile of DOR in
participants switching from efavirenz were found to be similar to those of participants
switching from other ARV therapies (10). From a physiological perspective, sustained
virologic suppression is not anticipated to impact the PK of DOR, consistent with the
findings of this analysis. The similarity of DOR PK between treatment-naive and switch
populations indicates that dose recommendations for DOR determined in the
treatment-naive population are directly applicable to the switch population without
adjustments and supports the appropriateness of the 100-mg dose of DOR within the
switch population.
Data availability. The data sharing policy of Merck Sharp & Dohme Corp., a subsidiary
of Merck & Co., Inc., Kenilworth, NJ, including restrictions, is available at http://engagezone
.msd.com/ds_documentation.php. Requests for access to the clinical study data can be























































































































FIG 2 Predicted and observed proportion of ISG participants maintaining HIV-1 RNA at (A) 50 copies/ml
or (B) 40 copies/ml using the snapshot approach as a function of DOR steady-state C24 quartiles
following administration of 100 mg once-daily DOR (N  443). Solid lines signify the mean predicted
exposure-response relationship. Shaded areas represent the 95% CI of the prediction over the 5th to 95th
percentiles of exposures. Markers and whiskers summarize the observed endpoint and 95% CI by C24
quantile. AUC0 –24, area under the concentration-time curve from 0 to 24 h; C24, plasma concentration
24 h after dose administration; Cmax, maximum serum drug concentration; DOR, doravirine; ISG, imme-
diate switch group.
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